Amen! Couldn't agree more
@Hawk70 As a current holder it's even more painful.
Yep, the two big issues for me are not having a clear funding pathway, and the lack of IP protection.
I'm not entirely sure of the genesis of the current NYR-BIO3 compound, but if it comes from Kelly's genistein / Veyonda work -- like earlier patent applications (see:
https://patents.google.com/patent/US20200215025A1/en ) then they might have some problems. We'll have to wait another 12 months until the patent is published.
NYR applied for another patent "Compounds for cancer treatment" at the same time last year, so I suspect it might all be part of the latest genistein / soybean grift.
(20min delay)